DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study
Denali announces encouraging additional longer-term data from the phase I/II Hunter Syndrome study of its investigational ...
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued ...
Denali Therapeutics announces primary analysis of Phase 1/2 study in MPS II
Denali Therapeutics (DNLI) announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome in the 24-week ...
Zacks Research Has Weak Estimate for DNLI FY2024 Earnings
Research analysts at Zacks Research decreased their FY2024 EPS estimates for shares of Denali Therapeutics in a research report issued on Tuesday, January 28th. Zacks Research analyst A. Chakraborty ...
Tracking Baillie Gifford's 13F Portfolio - Q4 2024 Update
Baillie Gifford's 13F portfolio shows changes in top holdings like Amazon and NVIDIA, with increased stakes in SEA Ltd. Read ...